TrialJournal for immunotherapy of cancer2019

An interim report on the investigator-initiated phase 2 study of pembrolizumab immunological response evaluation (INSPIRE).

Derek L Clouthier et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.